Highest-materiality recent filing
SINTX issues 255K shares, new warrant for 1.27M shares at $2.14
Issued 255,267 shares from abeyance to MedTech Ceramics for no additional consideration.
SINTX raises $5.0M via $4.5M private placement and $0.5M ATM offering
Private placement of 1,882,845 units at $2.39/unit for $4.5M gross proceeds; each unit includes one share and two warrants.
SINTX Technologies receives Nasdaq delisting notice for insufficient stockholders' equity
Received Nasdaq notice on May 22, 2026 for non-compliance with minimum $2.5M stockholders' equity; reported equity ~$904k.
SINTX signs supply agreement with Evonik for SiN/PEEK compound for 3D-printed implants
Evonik Corporation will manufacture SINTX's proprietary SiN/PEEK compound (U.S. Patent No. 10,806,831) at commercial scale.
SINTX Q3 2025 net loss narrows to $3.5M; FDA clearance for SINAPTIC wedge system
Net loss of $3.5M ($1.19 per share) vs $6.2M ($6.96 per share) in Q3 2024.
SINTX Technologies enters $6.4M ATM equity offering agreement with H.C. Wainwright
Aggregate offering price up to $6,413,876; commission rate 3.0% of gross proceeds.
SINTX raises ~$3.8M via warrant exercise inducement; issues new warrants at $4.79 strike
Inducement agreement with holders to exercise 1,099,431 existing warrants at $3.32/share for cash.
SINTX appoints Kevin Trask as CFO; salary $300K, RSUs, bonus eligibility
Kevin Trask appointed CFO effective September 4, 2025; salary set at $300,000 annually.
SINTX submits FDA 510(k) for silicon nitride foot/ankle implants, entering $750M market
Filed 510(k) for silicon nitride osteotomy wedges on July 22, 2025, targeting foot/ankle fusion.
Acquired all IP and designs for six foot/ankle implant systems; market valued at $750M growing to $1.38B by 2032.
SINTX refocuses on medical devices; Q1 cash doubles to $6.5M, cash burn halved
Cash on hand $6.5M at March 31, 2025, up from $3.6M at year-end 2024.
SINTX raises $5M in private placement at $3.45/sh with warrants exercisable at $3.32
Gross proceeds of $5.0M from sale of 1,449,287 shares/pre-funded warrants at $3.45 each.
SINTX Technologies Announces Stock Repurchase Program of Up to $500,000
Board authorized repurchase of up to $500,000 in common stock, representing about 20% of outstanding shares.
SINTX appoints Eric K. Olson as CEO and President effective August 1, 2024
Eric K. Olson named CEO and President, succeeding B. Sonny Bal who retired as CEO and becomes Chairman.
SINTX Technologies Resumes At-the-Market Equity Offering of Up to $3.1 Million
Company terminated previous ATM sales on March 22, 2024, after raising $15M under original agreement.
SINTX shareholders approve reverse stock split at ratio 1:100 to 1:300
Special meeting held May 14, 2024; quorum of 24,134,268 shares present.
SINTX Technologies CEO B. Sonny Bal to retire upon naming replacement; remains Chairman
B. Sonny Bal informed board on April 25, 2024 of intent to retire as President and CEO, effective when replacement is named.
Nasdaq notifies SINTX of delisting due to bid price at $0.10 or less for 10 consecutive days
Received delisting notice from Nasdaq on April 8, 2024; bid price closed at $0.10 or less for 10 consecutive days.
SINTX Technologies prices $1.5M public offering of 71.6M shares at $0.021/share
Priced public offering of 71.6M shares at $0.021/share for gross proceeds of ~$1.5M.
SINTX Technologies prices $1.3M public offering of 28.4M shares at $0.047/share
28,400,000 shares priced at $0.047 per share; gross proceeds ~$1.3M.
SINTX Technologies prices $4.0M public offering of 16M units at $0.25/unit
Gross proceeds expected ~$4M from 16M units (shares or pre-funded warrants plus Class E & F warrants).
SINTX reports prelim Q4 rev ~$902k, FY rev $2.6M, up 68% YoY
Q4 2023 revenue approx $902k and full year 2023 revenue $2.6M, both unaudited.
SINTX strengthens antipathogenic patent portfolio with six US and three foreign patents in 2023
Granted six US patents in the last year covering silicon nitride applications: antifungals, antibacterial implants, SARS-CoV-2 inactivation, antiviral compositions, antipathogenic face masks.
SINTX receives Nasdaq bid price deficiency notice; cure deadline April 2024
Received Nasdaq notice on Oct 20, 2023 due to bid price below $1.00 for 30 consecutive trading days.
SINTX awarded $1.97M NIH Phase II grant for 3D printed spinal implant
NIH Phase II SBIR grant of $1,972,826 to develop 3D printed silicon nitride-PEEK spinal implant.
SINTX prelim Q4 rev $770k, FY22 $1.6M; best annual revenue since 2018
Preliminary unaudited Q4 2022 revenue ~$770k; full year 2022 revenue $1.6M.
SINTX announces 1-for-100 reverse stock split effective Dec 20, 2022
Reverse split ratio set at 1-for-100, effective 12:01 a.m. ET on Dec 20, 2022.
SINTX Technologies receives Nasdaq delisting notice over $0.10 rule; seeks hearing
Nasdaq notified SINTX on Nov 17, 2022 that its bid price closed below $0.10 for 10 consecutive days, triggering delisting under Listing Rule 5810(3)(A)(iii).
The Board of Directors of SINTX Technologies, Inc. (the “Company”) appointed Jay M. Moyes, Robert D. Mitchell, Mark Anderson, Chris Lyons and Gregg Honigblum to the Board of Directors of the Company, effective April 3, 2025.
The Board of Directors of SINTX Technologies, Inc. (the “Company”) appointed Jay M. Moyes, Robert D. Mitchell, Mark Anderson, Chris Lyons and Gregg Honigblum to the Board of Directors of the Company, effective April 3, 2025.
The Board of Directors of SINTX Technologies, Inc. (the “Company”) appointed Jay M. Moyes, Robert D. Mitchell, Mark Anderson, Chris Lyons and Gregg Honigblum to the Board of Directors of the Company, effective April 3, 2025.
The Board of Directors of SINTX Technologies, Inc. (the “Company”) appointed Jay M. Moyes, Robert D. Mitchell, Mark Anderson, Chris Lyons and Gregg Honigblum to the Board of Directors of the Company, effective April 3, 2025.
The Board of Directors of SINTX Technologies, Inc. (the “Company”) appointed Jay M. Moyes, Robert D. Mitchell, Mark Anderson, Chris Lyons and Gregg Honigblum to the Board of Directors of the Company, effective April 3, 2025.
On March 7, 2025, the Board of Directors of SINTX Technologies, Inc. (the “Company”) appointed Eric K. Olson to the position of Chairman of the Board of Directors.
In connection with Mr. Olson’s appointment, B. Sonny Bal stepped down as Chairman of the Board and continues to serve on the Company’s Board of Directors.
The Board of Directors of SINTX Technologies, Inc. (the “Company”) has appointed its Chief Executive Officer and President, Eric K. Olson, to the Board of Directors of the Company, effective November 22, 2024.
Gregg Honigblum has been appointed to serve as SINTX Technologies, Inc.’s (the “Company”) Chief Strategy Officer effective November 15, 2024.
On July 31, 2024, the Board of Directors of SINTX Technologies, Inc. (the “Company”) appointed Eric K. Olson as Chief Executive Officer and President with such appointment effective August 1, 2024.
In connection with Mr. Olson’s appointment, B. Sonny Bal retired from his position as Chief Executive Officer and President and now serves as Chairman of the Board.
on April 25, 2024, B. Sonny Bal, MD, informed the board of directors of his intention to retire from his position as President and Chief Executive Officer of SINTX Technologies, Inc.
Max materiality 0.85 · Median 0.60 · Most common event other_material